Search

Displaying results 4471 - 4480 of 7059 in total
  1. Drug

    Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase

    go.drugbank.com/drugs/DB18681
    Experimental

    It comprises autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that had been genetically modified ex vivo with EFS-ADA LV.

  2. Drug

    Propidium

    go.drugbank.com/drugs/DB02166
    Experimental

    Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Selinexor

    go.drugbank.com/drugs/DB11942
    ApprovedInvestigational

    [L10145] The FDA approved Selinexor in June 2019. … Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound.

  4. Drug

    BK-MDA

    go.drugbank.com/drugs/DB12809
    Investigational

    BK-MDA has been used in trials studying the treatment of Bladder Exstrophy and Urinary Incontinence.

    Synonyms: BK-MDA
  5. Drug

    Febuxostat

    go.drugbank.com/drugs/DB04854
    ApprovedInvestigational

    Febuxostat is a non-purine xanthine oxidase (XO) inhibitor. … [L32238] Gout is a form of arthritis that is caused by the accumulation of uric acid crystal in or around a joint, leading to inflammation and further deposition of uric acid crystal deposition in bones

    Products: FEBUXOSTAT 1A PHARMA 80MG, FEBUXOSTAT 1A PHARMA 120MG
  6. Drug

    SBT-100

    go.drugbank.com/drugs/DB17215
    Experimental

    It was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma.[L44131,L44136]

  7. Drug

    Ovatodiolide

    go.drugbank.com/drugs/DB19264
    Investigational

    Ovatodiolide is under investigation in clinical trial NCT04220411 (A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD)).

    Synonyms: (3as,6e,13s,15e,16ar)-3a,4,5,8,9,13,14,16a-octahydro-6,15-dimethyl-3-methylene-11h-13,10-methenofuro(2,3-f)oxacyclopentadecin-2,11(3h)-dione, 11h-13,10-methenofuro(2,3-f)oxacyclopentadecin-2,11(3h)-dione, 3a,4,5,8,9,13,14,16a-octahydro-6,15-dimethyl-3-methylene-, (3as,6e,13s,15e,16ar)-
  8. Drug

    10-hydroxycamptothecin

    go.drugbank.com/drugs/DB12385
    Experimental

    10-hydroxycamptothecin is under investigation in clinical trial NCT00956787 (Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)).

  9. Drug

    XL844

    go.drugbank.com/drugs/DB05149
    Investigational

    XL844 is a solid. XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents.

  10. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index